C.R. Bard, Inc. recalls I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated

Recalled December 27, 2017 · FDA recall Z-0267-2018 · C.R. Bard

Hazard

Activity and quantity of seeds sent in shipments were incorrect. · FDA Class II

Units

134 seeds

Sold at

Belgium & South Africa.

Description

Activity and quantity of seeds sent in shipments were incorrect.

Product

I-125 CE Marked QuickLink Cartridges; Sterile; Bard Brachysource Radioactive Seeds in QuickLink Cartridges Indicated for permanent interstitial treatment of selected localized tumors such as: head and neck, lung, pancreas, and early stage prostate. Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.

Manufacturer(s)

C.R. Bard, Inc.

Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →